Home /Research /Comment on The Unbearable Lightness of Difference Between Statistical and Clinical Significance
SURGICAL

Comment on The Unbearable Lightness of Difference Between Statistical and Clinical Significance

Luca Bertolaccini, Oriana Ciani, Lorenzo Spaggiari

Year
2022
Citations
6

Abstract

In the latest issue of Annals of Surgery, Jin et al compared the efficacy of robotic-assisted (RATS) lobectomy and video-assisted (VATS) lobectomy in a single-center, open-label, parallel-arm noninferiority randomized clinical trial. They concluded that both approaches were safe and feasible, but RATS resulted in a more significant number of lymph nodes harvested.1 These results partially confirm the findings of a recent meta-analysis, where RATS was demonstrated as a feasible and safe technique with surgical efficacy comparable to VATS.2 The short-term results of the RVlob Trial are that the total number of lymph nodes dissected (11 vs 10) and the number of nodal stations examined were greater with RATS than with VATS (6 vs 5). Additionally, a more significant number of lymph nodes were dissected in N1 stations (6 vs 5) whether N2 stations remained constant (5 in both approaches).1 A previous meta-analysis showed that the number of dissected lymph nodes number comparing RATS with VATS does not reach a statistically significant level (>10 lymph nodes dissected).2 Nevertheless, it was demonstrated that examining more lymph nodes increases the likelihood of proper staging and influences the patient outcome. This information is critical for individual treatment and prognosis and for identifying those who benefit from adjuvant therapy.3 It was demonstrated that patients who undergo pulmonary lobectomy or pneumonectomy should have at least 12 lymph nodes examined.4 Nevertheless, when interpreting clinical evidence, 3 questions should be asked: How trustworthy are the findings? Are the results purely coincidental? Are the results meaningful to patient?5 Most journals now endorse the extension of the CONSORT 2019 statement for reporting noninferiority and equivalence randomised trials.6 Nonetheless, a common pitfall of this and other trial reports is the misinterpretation of statistical significance as clinical significance. The misunderstanding stems from the fact that many people associate significance with its literal meaning of significance, whereas in statistics, it has a much more restrictive connotation. In clinical practice, the clinical significance of study results is determined by their implications for current practice, with treatment effect size being one of the primary factors influencing treatment decisions. Clinical significance should be determined by the magnitude of the change, its effect on subject lives, the duration of the effects, consumer acceptability, cost-effectiveness, and ease of implementation. While established, traditionally accepted values exist for statistical significance testing, they do not exist for clinical significance evaluation. Often, the clinician’s judgment determines whether a result is clinically significant or not.7 Therefore, even statistically significant, the reported difference of only one lymph node dissected in the different nodal stations is clinically insignificant. Among the secondary endpoints of the evaluation, the authors considered direct and indirect costs of the hospitalisation. According to widely used guidelines for the economic evaluation of healthcare interventions, direct costs include all costs directly related to the intervention of interest, borne inside the healthcare sector (eg, materials, equipment, personnel, and services) as well as outside the healthcare sector (eg, patients’ travel time). Indirect costs include a temporary absence from work due to illness, reduced working capacity due to illness and disability, or lost productivity due to early death. While there is an increasing interest toward measuring the indirect costs of healthcare treatments to quantify the value of innovative therapies from a broader societal perspective, what the authors report as indirect costs, does not cover this evidentiary gap. Indeed, the level of details provided on the cost analysis (eg, lack of reporting of monetary unitary values and their sources) is not sufficient to ap

Keywords

LymphMedicineLymph nodePneumonectomyClinical trialSurgeryPathologyInternal medicineLung

Related papers

Browse all SURGICAL papers